UY37005A - Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos - Google Patents

Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos

Info

Publication number
UY37005A
UY37005A UY2016037005A UY37005A UY37005A UY 37005 A UY37005 A UY 37005A UY 2016037005 A UY2016037005 A UY 2016037005A UY 37005 A UY37005 A UY 37005A UY 37005 A UY37005 A UY 37005A
Authority
UY
Uruguay
Prior art keywords
hydroxypyrimidinones
agelists
apelina
receiver
replaced
Prior art date
Application number
UY2016037005A
Other languages
English (en)
Inventor
Wei Meng
J Chao Hannguang
Hather Finlay
Michael Lawrence R
C Myers Michael
Original Assignee
Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware filed Critical Bristol-Myers Squibb Company Una Corporacion Del Estado De Delaware
Publication of UY37005A publication Critical patent/UY37005A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona compuestos de la Fórmula (I): en donde todas las variables son como se definen en la memoria descriptiva, y composiciones que comprenden cualquiera de tales compuestos novedosos. Estos compuestos son agonistas de APJ que se pueden usar como medicamentos.
UY2016037005A 2015-12-04 2016-12-02 Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos UY37005A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562263106P 2015-12-04 2015-12-04

Publications (1)

Publication Number Publication Date
UY37005A true UY37005A (es) 2017-06-30

Family

ID=57570463

Family Applications (1)

Application Number Title Priority Date Filing Date
UY2016037005A UY37005A (es) 2015-12-04 2016-12-02 Hidroxipirimidinonas sustituidas como agonistas del receptor de apelina y sus usos

Country Status (20)

Country Link
US (2) US11390616B2 (es)
EP (1) EP3383860B1 (es)
JP (1) JP6817305B2 (es)
KR (1) KR102678264B1 (es)
CN (1) CN108473466B (es)
AR (1) AR106948A1 (es)
AU (1) AU2016365340B2 (es)
BR (1) BR112018010720A8 (es)
CA (1) CA3007280A1 (es)
CL (1) CL2018001478A1 (es)
CO (1) CO2018006662A2 (es)
EA (1) EA037257B1 (es)
ES (1) ES2858312T3 (es)
HK (1) HK1255162A1 (es)
IL (1) IL259660B (es)
MX (1) MX381160B (es)
PE (1) PE20181269A1 (es)
TW (1) TW201722920A (es)
UY (1) UY37005A (es)
WO (1) WO2017096130A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
AU2016263564B2 (en) 2015-05-20 2019-12-05 Amgen Inc. Triazole agonists of the APJ receptor
CA2988147C (en) 2015-06-03 2023-06-13 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
PE20181197A1 (es) 2015-10-14 2018-07-23 Bristol Myers Squibb Co 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
BR112018010720A8 (pt) 2015-12-04 2019-02-26 Bristol Myers Squibb Co agonistas do receptor de apelina e métodos de uso
ES2854733T3 (es) 2015-12-16 2021-09-22 Bristol Myers Squibb Co Heteroarilhidroxipirimidinonas como agonistas del receptor APJ
TWI744301B (zh) 2016-03-24 2021-11-01 美商必治妥美雅史谷比公司 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
ES2844184T3 (es) 2016-06-14 2021-07-21 Bristol Myers Squibb Co 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ
WO2017218633A1 (en) * 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
CN110072850B (zh) 2016-10-14 2023-07-21 百时美施贵宝公司 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
EP3759095A1 (en) * 2018-03-01 2021-01-06 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
EP4360632B1 (en) 2019-01-15 2025-10-29 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
DE4425616A1 (de) 1994-07-20 1996-01-25 Basf Ag Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
JPH08325248A (ja) 1995-05-26 1996-12-10 Chugoku Kayaku Kk テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法
BR9711098B1 (pt) 1996-07-01 2011-10-04 compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
EP1301490A2 (en) 2000-07-18 2003-04-16 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
EP1476165A1 (en) 2002-02-22 2004-11-17 PHARMACIA & UPJOHN COMPANY Substituted pyrimidinones and pyrimidinthiones
BRPI0409649A (pt) 2003-04-23 2006-04-25 Pharmacia & Upjohn Co Llc pirimidinonas e pirimidinotionas substituìdas como antagonistas de crf
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
EP1697331A4 (en) 2003-12-19 2010-08-04 Merck Sharp & Dohme INHIBITORS OF MITOTIC KINESINE
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
CA2630884A1 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
EP1903052A3 (en) * 2006-07-28 2008-04-02 Faust Pharmaceuticals SA APJ receptor ligands and uses thereof
US9212130B2 (en) 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
US20140005181A1 (en) 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
US20140073634A1 (en) 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
ES2623528T3 (es) * 2012-09-21 2017-07-11 Sanofi Derivados de amida de ácido benzoimidazolcarboxílico para tratar enfermedades metabólicas o cardiovasculares
CA2988147C (en) 2015-06-03 2023-06-13 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
PE20181197A1 (es) 2015-10-14 2018-07-23 Bristol Myers Squibb Co 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
BR112018010720A8 (pt) 2015-12-04 2019-02-26 Bristol Myers Squibb Co agonistas do receptor de apelina e métodos de uso
ES2854733T3 (es) 2015-12-16 2021-09-22 Bristol Myers Squibb Co Heteroarilhidroxipirimidinonas como agonistas del receptor APJ
TWI744301B (zh) 2016-03-24 2021-11-01 美商必治妥美雅史谷比公司 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
ES2844184T3 (es) 2016-06-14 2021-07-21 Bristol Myers Squibb Co 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ
WO2017218633A1 (en) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
CN110072850B (zh) 2016-10-14 2023-07-21 百时美施贵宝公司 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂

Also Published As

Publication number Publication date
JP6817305B2 (ja) 2021-01-20
BR112018010720A2 (pt) 2018-11-21
KR102678264B1 (ko) 2024-06-24
US11390616B2 (en) 2022-07-19
EP3383860B1 (en) 2021-01-20
IL259660A (en) 2018-07-31
PE20181269A1 (es) 2018-08-03
MX381160B (es) 2025-03-12
EP3383860A1 (en) 2018-10-10
CO2018006662A2 (es) 2018-07-10
BR112018010720A8 (pt) 2019-02-26
AR106948A1 (es) 2018-03-07
AU2016365340B2 (en) 2021-05-27
US20220315569A1 (en) 2022-10-06
TW201722920A (zh) 2017-07-01
AU2016365340A1 (en) 2018-07-19
CN108473466A (zh) 2018-08-31
CN108473466B (zh) 2022-04-19
CA3007280A1 (en) 2017-06-08
US12168655B2 (en) 2024-12-17
US20210198246A1 (en) 2021-07-01
HK1255162A1 (zh) 2019-08-09
JP2018535999A (ja) 2018-12-06
MX2018006217A (es) 2018-08-01
CL2018001478A1 (es) 2018-09-14
IL259660B (en) 2021-01-31
EA037257B1 (ru) 2021-02-26
ES2858312T3 (es) 2021-09-30
KR20180086251A (ko) 2018-07-30
WO2017096130A1 (en) 2017-06-08
EA201891344A1 (ru) 2018-12-28

Similar Documents

Publication Publication Date Title
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CO2018004968A2 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CO2018007221A2 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
CL2018002671A1 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj)
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
MX377610B (es) Agonistas del receptor de glucagon.
MX387587B (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos.
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
MX387055B (es) Agonistas del receptor de apelina (apj) y usos de los mismos.
MX2016012103A (es) Agonistas del receptor muscarinico.
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
MX381643B (es) Compuestos heteroarilo bicíclicos sustituidos como agonistas rxr.
BR112018002087A2 (pt) pró-fármacos de análogos de glutamina
UY36086A (es) Compuestos de quinoxalina y usos de los mismos